Vijaya Diagnostic Centre Ltd. (VIJAYA) AI Stock Analysis

• Market Cap: ₹108.14B
• Dividend Yield: 0.19%
• Average Volume (3M): 4.81K
• Price to Earnings (P/E): 72.0
• Beta (1Y): 0.38
• Revenue Growth: 22.34%
• EPS Growth: 20.71%
• Country: IN
• Employees: 2,053
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 3.70
• Shares Outstanding: 102,724,940
• 10 Day Avg. Volume: 2,777
• 30 Day Avg. Volume: 4,813
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,064.00
• Price Target Upside: 2.30% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 2

• Rating: 68 Neutral
• Price Target: ₹1,136.00 ▲(9.23% Upside)

Vijaya Diagnostic Centre Ltd. demonstrates strong financial performance with robust revenue growth and profitability, which is the most significant factor in the overall score. However, technical indicators suggest potential bearish momentum, and the high P/E ratio indicates overvaluation concerns. The low dividend yield further impacts the valuation score. The absence of earnings call data and corporate events means these factors do not influence the overall score.

Vijaya Diagnostic Centre Ltd. Business Overview & Revenue Model

Company Description

Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. It offers laboratory services, including clinical biochemistry, haematology and immune-haematology, clinical pathology, histopathology and cytopathology, microbiology, serology, cytogenetics, and molecular pathology; radiology and imaging services comprising magnetic resonance imaging, multi slice CT, CBCT (3D dental), mammography, DEXA/bone densitometry, ultrasound/color doppler, nuclear medicine and PET/CT, and digital X-ray; and cardiology, neurology, and gastroenterology services. The company also provides health checkups and home sample collection services. It has a network, which consists of 80 diagnostic center and 11 reference laboratories across 13 cities and towns in the states of Telangana and Andhra Pradesh, and in the National Capital Region and Kolkata. The company was founded in 1981 and is based in Hyderabad, India.

How the Company Makes Money

Vijaya Diagnostic Centre Ltd. makes money primarily through the provision of diagnostic testing services across its network of centers. Key revenue streams include fees charged for pathology tests, which involve the examination of blood, urine, and other bodily fluids, and radiology tests such as X-rays, MRIs, and CT scans. The company's revenue is driven by the demand for these diagnostic services from individual patients, healthcare providers, and corporate clients. Additionally, Vijaya Diagnostic Centre may engage in partnerships with hospitals and clinics to provide outsourced diagnostic services, contributing to its earnings.

Vijaya Diagnostic Centre Ltd. Financial Statement Overview

Summary

Vijaya Diagnostic Centre Ltd. exhibits a strong financial position marked by significant revenue growth, high profitability margins, and efficient cash flow management. The balance sheet reflects low leverage and solid equity standing, while cash flows show positive trends and solid operational cash generation. The company is well-positioned for continued growth, though maintaining low liabilities would further enhance financial stability.

Income Statement

The company demonstrates strong revenue growth with a 24.38% increase from 2024 to 2025. Gross profit margin is impressive at 87.58%, and net profit margin has improved to 21.00%. EBIT and EBITDA margins are robust at 71.10% and 40.10%, respectively, indicating efficient operations and cost management. Overall, the income statement reflects positive growth and profitability trends.

Balance Sheet

The balance sheet shows a solid equity base with a debt-to-equity ratio of 0.40, which indicates low leverage. The company maintains a good equity ratio of 62.47%, highlighting financial stability. Return on equity is strong at 17.98%, reflecting effective use of equity to generate profits. The balance sheet is healthy, though there is room for improvement in reducing liabilities further.

Cash Flow

Operating cash flow is strong, translating into a high operating cash flow to net income ratio of 1.57. Free cash flow shows positive growth, increasing by 35.20% from the previous period. The free cash flow to net income ratio of 0.90 indicates effective cash management and ability to generate cash from operations. Overall, cash flow is robust, supporting the company's growth and operational needs.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.81B	6.81B	5.48B	4.59B	4.62B	3.76B
Gross Profit	5.53B	5.97B	4.61B	4.00B	3.91B	3.19B
EBITDA	2.85B	2.73B	2.39B	1.96B	2.16B	1.77B
Net Income	1.43B	1.43B	1.19B	846.32M	1.10B	844.78M
Balance Sheet
Total Assets	12.74B	12.74B	9.83B	8.53B	7.13B	5.41B
Cash, Cash Equivalents and Short-Term Investments	2.33B	2.33B	1.82B	2.55B	2.25B	2.20B
Total Debt	3.20B	3.20B	2.59B	2.48B	1.83B	1.41B
Total Liabilities	4.74B	4.74B	3.23B	3.07B	2.44B	1.82B
Stockholders Equity	7.96B	7.96B	6.57B	5.45B	4.68B	3.59B
Cash Flow
Free Cash Flow	0.00	1.29B	953.37M	397.69M	356.50M	975.07M
Operating Cash Flow	0.00	2.24B	1.83B	1.65B	1.58B	1.30B
Investing Cash Flow	0.00	-1.82B	-1.42B	-1.10B	-1.23B	-1.30B
Financing Cash Flow	0.00	-520.48M	-445.50M	-419.12M	-305.72M	-487.69M

Vijaya Diagnostic Centre Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1040.05
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIJAYA, the sentiment is Negative. The current price of 1040.05 is below the 20-day moving average (MA) of 1055.84, below the 50-day MA of 1053.20, and above the 200-day MA of 1025.00, indicating a neutral trend. The MACD of 0.38 indicates Positive momentum. The RSI at 46.53 is Neutral, neither overbought nor oversold. The STOCH value of 26.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VIJAYA.

Vijaya Diagnostic Centre Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIJAYA	68 Neutral	₹108.14B	71.98	―	0.19%	22.34%	20.71%
METROPOLIS	68 Neutral	107.74B	70.44	10.89%	―	12.86%	10.42%
KRSNAA	63 Neutral	27.44B	34.90	8.79%	0.32%	13.78%	32.21%
HCG	61 Neutral	90.65B	244.45	4.81%	―	16.85%	-29.57%
UNICHEMLAB	58 Neutral	34.54B	26.40	5.61%	―	22.04%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Vijaya Diagnostic Centre Ltd. Corporate Events

Vijaya Diagnostic Centre Secures Shareholder Approval for Key Resolution

Vijaya Diagnostic Centre Ltd. announced the successful passing of a resolution by its equity shareholders during a court-convened general meeting. The resolution was approved by a majority of shareholders, including both promoter and public shareholders, indicating strong support for the company’s proposed actions. This outcome may positively impact the company’s strategic operations and reinforce its market position.